New cancer drug combo tested in patients out of options
Disease control
Completed
This early-stage trial tested the safety and dosing of a new cancer drug called ADG116, both alone and combined with other immune-boosting drugs, in patients with advanced solid tumors that have spread. The study involved 72 adults whose cancer had progressed despite standard tre…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC